-
2024-510893-25-00
5
2025-04-29
Brain metastases of cancer > brain radionecrosis
-
2024-513084-38-00
9
2025-04-15
Recently diagnosed non favorable Acute Myeloid Leukemias
-
2024-511357-22-00
4
2025-03-31
Crohn's disease
-
2024-513547-82-00
5
2025-03-11
Transthyretin Amyloidosis
-
2023-509538-20-01
1
2025-03-06
Primary Progressive Multiple Sclerosis
-
2023-508535-32-00
4
2025-03-04
Portal hypertension (PHT) and consequences in complications of cirrhos
-
2023-509787-15-00
5
2025-02-17
Patients with localised prostate cancer and high-risk features of rela
-
2022-502352-31-00
5
2025-02-10
Colorectal Cancer (CRC)
-
2024-510772-20-00
4
2025-02-06
Rectal cancer locally advanced with microsatellite unstable or mismatc
-
2024-513128-40-00
4
2025-02-06
Multifocal Motor Neuropathy
-
2024-510805-27-00
5
2025-01-09
Sickle Cell Disease and Thalassaemia
-
2023-507254-32-00
5
2024-12-17
Severe hyponatremia and a high risk of rapid SNa overcorrection
-
2024-514983-23-01
9
2024-12-16
Intermediate-risk Non-muscle Invasive Bladder Cancer
-
2024-516709-22-00
10
2024-12-16
metastatic colorectal cancer carcinoma
-
2024-512895-36-00
5
2024-11-25
Non Alcoholic Steatohepatitis (NASH)
-
2024-516744-26-00
4
2024-11-15
acute osteomyelitis of the child
-
2024-516242-19-00
5
2024-11-05
lupus nephritis
-
2023-509340-10-00
5
2024-10-29
Patients with HLA-A2 positive phenotype and metastatic Non-Small Cell
-
2024-514606-31-00
4
2024-10-29
Patients with Biopsy-proven or radiologically-suggested BCLC A HCC eli
-
2024-516101-23-00
5
2024-10-28
Sarcoidosis
-
2024-511319-91-00
5
2024-10-23
Advanced non-small cell lung cancer with HER2 (ERBB2) mutation
-
2023-504755-26-00
4
2024-10-21
Bronchiectasis
-
2022-502408-57-00
5
2024-09-04
Novo metastatic hormone-sensitive prostate cancer (mHSPC) patients hav
-
2023-506216-40-00
5
2024-08-14
CytoMegaloVirus infections